Subtopic Deep Dive
Nintedanib for Pulmonary Fibrosis
Research Guide
What is Nintedanib for Pulmonary Fibrosis?
Nintedanib is an oral tyrosine kinase inhibitor approved for slowing forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung diseases.
Two phase III trials (INPULSIS-1 and INPULSIS-2) demonstrated nintedanib reduces annual FVC decline by approximately 50 mL/year in IPF patients (Richeldi et al., 2014; 4357 citations). The INBUILD trial extended efficacy to progressive fibrosing interstitial lung diseases beyond IPF (Flaherty et al., 2019; 2157 citations). Its mechanism involves inhibition of fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors (Wollin et al., 2015; 928 citations).
Why It Matters
Nintedanib's approval by FDA in 2014 for IPF and EMA in 2019 for progressive fibrosing ILDs expanded treatment options, reducing FVC decline and delaying disease progression (Richeldi et al., 2014; Flaherty et al., 2019). ATS/ERS/JRS/ALAT guidelines recommend nintedanib for IPF patients with FVC >50% predicted (Raghu et al., 2022; 2302 citations). Ongoing research explores its role in systemic sclerosis-associated ILD, showing FVC preservation (Distler et al., 2019; 1497 citations), and potential post-COVID fibrosis prevention (George et al., 2020; 1094 citations).
Key Research Challenges
Long-term Safety Concerns
Diarrhea occurs in over 60% of patients, leading to 20% discontinuation rates in trials (Richeldi et al., 2014). Long-term data beyond 52 weeks remain limited despite extensions (Flaherty et al., 2019). Balancing efficacy against gastrointestinal adverse events requires monitoring strategies.
Comparative Effectiveness
No head-to-head trials exist with pirfenidone, the other approved IPF antifibrotic (Raghu et al., 2022). Indirect comparisons show similar FVC benefits but differing side effects (Martínez et al., 2017). Real-world evidence is needed for combination therapy feasibility.
Expanding Indications
Efficacy in non-IPF fibrosing ILDs varies by subtype, with unproven benefits in some (Flaherty et al., 2019). Biomarkers for responders are absent (Wollin et al., 2015). Trials in post-transplant fibrosis or COVID-related fibrosis lack completion (George et al., 2020).
Essential Papers
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · 2014 · New England Journal of Medicine · 4.4K citations
In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea,...
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu, Martine Remy-Jardin, Luca Richeldi et al. · 2022 · American Journal of Respiratory and Critical Care Medicine · 2.3K citations
<b>Background:</b> This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary f...
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · 2019 · New England Journal of Medicine · 2.2K citations
In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received...
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · 2019 · New England Journal of Medicine · 1.5K citations
Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other m...
Idiopathic pulmonary fibrosis
Fernando J. Martínez, Harold R. Collard, Annie Pardo et al. · 2017 · Nature Reviews Disease Primers · 1.3K citations
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Jamie N. Justice, Anoop M. Nambiar, Tamar Tchkonia et al. · 2019 · EBioMedicine · 1.1K citations
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
Peter M. George, Athol U. Wells, Gísli Jenkins · 2020 · The Lancet Respiratory Medicine · 1.1K citations
Reading Guide
Foundational Papers
Start with Richeldi et al. (2014; 4357 citations) for IPF phase III trial results establishing FVC as primary endpoint, then Wollin et al. (2015; 928 citations) for kinase inhibition mechanism.
Recent Advances
Study Flaherty et al. (2019; 2157 citations) for pf-ILD expansion, Raghu et al. (2022; 2302 citations) for updated guidelines, and Distler et al. (2019; 1497 citations) for SSc-ILD data.
Core Methods
Core methods include randomized double-blind placebo-controlled trials measuring annual FVC decline, high-resolution CT for progression confirmation, and tyrosine kinase assays in preclinical models.
How PapersFlow Helps You Research Nintedanib for Pulmonary Fibrosis
Discover & Search
Research Agent uses searchPapers and citationGraph on 'nintedanib IPF' to map 4357-citation INPULSIS trial (Richeldi et al., 2014) to INBUILD (Flaherty et al., 2019), revealing 2157-citation progression in fibrosing ILDs. exaSearch uncovers mechanism papers like Wollin et al. (2015). findSimilarPapers links to Distler et al. (2019) for SSc-ILD applications.
Analyze & Verify
Analysis Agent applies readPaperContent to extract FVC decline rates from Richeldi et al. (2014), then runPythonAnalysis with pandas to compute 95% CIs from trial data tables. verifyResponse (CoVe) cross-checks claims against Raghu et al. (2022) guidelines; GRADE grading scores INPULSIS evidence as high-quality for IPF recommendation.
Synthesize & Write
Synthesis Agent detects gaps in long-term safety data beyond INPULSIS extensions, flags contradictions between IPF and pf-ILD efficacy profiles. Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 10+ papers, and latexCompile for manuscript export. exportMermaid visualizes nintedanib's kinase inhibition pathways from Wollin et al. (2015).
Use Cases
"Run meta-analysis on nintedanib FVC decline across IPF trials"
Research Agent → searchPapers('nintedanib FVC IPF') → Analysis Agent → readPaperContent(Richeldi 2014 + Flaherty 2019) → runPythonAnalysis(pandas meta-analysis, forest plot) → researcher gets CSV of pooled effect size (-125 mL/year) with CI.
"Draft LaTeX review section on nintedanib mechanisms and trials"
Synthesis Agent → gap detection(INPULSIS to INBUILD) → Writing Agent → latexEditText(structured section) → latexSyncCitations(8 papers) → latexCompile(PDF) → researcher gets formatted review with FVC graphs and cited abstracts.
"Find code for modeling nintedanib pharmacokinetics in fibrosis"
Research Agent → paperExtractUrls(Wollin 2015) → paperFindGithubRepo(pharmacokinetic models) → githubRepoInspect → researcher gets Python scripts simulating kinase inhibition from validated repos linked to nintedanib preclinical data.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(250+ nintedanib hits) → citationGraph(INPULSIS cluster) → DeepScan(7-step: extract FVC, GRADE, Python stats) → structured report on efficacy/safety. Theorizer generates hypotheses on nintedanib combos from Raghu 2022 guidelines + Distler 2019. Chain-of-Verification ensures no hallucinated trial outcomes.
Frequently Asked Questions
What defines nintedanib's primary mechanism in pulmonary fibrosis?
Nintedanib inhibits VEGF, FGF, and PDGF receptors, reducing fibroblast proliferation and ECM deposition (Wollin et al., 2015).
What were the key phase III trials for nintedanib in IPF?
INPULSIS-1 and INPULSIS-2 showed 125 mL/year less FVC decline vs placebo (Richeldi et al., 2014; 4357 citations).
Which key papers established nintedanib's efficacy?
Richeldi et al. (2014) for IPF; Flaherty et al. (2019) for progressive fibrosing ILDs; Distler et al. (2019) for SSc-ILD.
What are open problems in nintedanib research?
Lack of head-to-head vs pirfenidone trials, biomarkers for responders, and long-term data in non-IPF fibroses (Raghu et al., 2022).
Research Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Nintedanib for Pulmonary Fibrosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers